Security
Relmada Therapeutics, Inc. Common Stock · RLMD
RLMDNASDAQCommon stockCurrentCIK 1553643Updated Oct 6, 2026
Name history
CAMP NINE, INC. · through Jul 14, 2014
RLMD price & chart
Loading TradingView…
NASDAQ:RLMD on TradingView ↗About the company
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01
SCHEDULE 13G/A - filed by Squadron Capital Management LLC regarding RELMADA THERAPEUTICS, INC.
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 14,876,244Source | 55,724,505Source | 219,059,177Source | 21,116,144Source | 71,028,476Source | 235,362,794Source | 27,679,417Source | 84,408,164Source | 94,003,471Source | 45,817,818Source | 97,552,042Source | 152,905,179Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,384,484Source | 1,483,789Source | 11,334,370Source | 1,353,351Source | 2,086,260Source | 9,776,400Source | 1,149,706Source | 1,335,018Source | 3,496,540Source | 3,857,026Source | 4,091,568Source | 5,395,905Source |
| Assets, CurrentUSD | 14,854,269Source | 55,702,530Source | 219,039,677Source | 21,094,169Source | 70,974,851Source | 235,343,294Source | 27,657,442Source | 84,365,039Source | 93,983,971Source | 45,795,843Source | 97,508,917Source | 152,870,304Source |
| Other Assets, NoncurrentUSD | 21,975Source | 21,975Source | 19,500Source | 21,975Source | 53,625Source | 19,500Source | 21,975Source | 43,125Source | 19,500Source | 21,975Source | 43,125Source | 34,875Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 5,410,705Source | 8,099,323Source | 12,500,854Source | 5,166,663Source | — | 16,630,217Source | 5,238,926Source | 12,361,833Source | 7,491,458Source | 10,295,857Source | 12,194,800Source | 12,468,877Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 33,191Source | 30,174Source | 106,670Source | 33,191Source | 30,174Source | 104,890Source | 33,191Source | 30,174Source | 73,333Source | 30,174Source | 30,099Source | 30,099Source |
| Additional Paid in CapitalUSD | 687,831,786Source | 669,819,907Source | 936,684,992Source | 684,224,232Source | 661,960,383Source | 935,946,841Source | 680,848,800Source | 654,746,964Source | 784,705,878Source | 676,373,822Source | 646,229,824Source | 602,517,138Source |
| Retained Earnings (Accumulated Deficit)USD | -678,399,438Source | -622,224,899Source | -730,233,339Source | -668,307,942Source | -600,498,929Source | -717,319,154Source | -658,441,500Source | -582,730,807Source | -698,267,198Source | -640,882,035Source | -560,902,681Source | -462,110,935Source |
| Stockholders' Equity Attributable to ParentUSD | 9,465,539Source | 47,625,182Source | 206,558,323Source | 15,949,481Source | 61,491,628Source | 218,732,577Source | 22,440,491Source | 72,046,331Source | 86,512,013Source | 35,521,961Source | 85,357,242Source | 140,436,302Source |
| Liabilities and EquityUSD | 14,876,244Source | 55,724,505Source | 219,059,177Source | 21,116,144Source | 71,028,476Source | 235,362,794Source | 27,679,417Source | 84,408,164Source | 94,003,471Source | 45,817,818Source | 97,552,042Source | 152,905,179Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 5,189,598Source | 8,086,761Source | 7,420,773Source | 5,134,547Source | 9,536,848Source | 12,891,634Source | 5,231,421Source | 12,361,833Source | 6,430,527Source | 10,291,390Source | 12,194,800Source | 12,468,877Source |
| Accounts Payable, CurrentUSD | 1,453,102Source | 2,345,541Source | 2,409,190Source | 1,361,911Source | 4,174,568Source | 5,731,401Source | 1,265,010Source | 5,189,101Source | 1,568,944Source | 4,130,563Source | 3,506,009Source | 5,261,936Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 3,736,496Source | 5,741,220Source | 5,011,583Source | 3,772,636Source | 5,362,280Source | 7,160,233Source | 3,966,411Source | 7,172,732Source | 4,861,583Source | 6,160,827Source | 8,688,791Source | 7,206,941Source |
| Short-term InvestmentsUSD | 12,502,040Source | 52,633,938Source | 206,396,805Source | 19,266,190Source | 68,351,069Source | 224,186,743Source | 25,911,326Source | 82,277,687Source | 89,509,710Source | 41,052,356Source | 92,232,292Source | 142,926,781Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 956,186Source | 3,572,769Source | 13,905,181Source | 30,184,414Source | 43,811,149Source | 44,194,765Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | — | — | 512,432Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,762,457Source | -2,865,553Source | -2,561,619Source | 624,554Source | -1,755,927Source | 421,040Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -15,067,488Source | -18,067,033Source | -45,786,988Source | -51,755,798Source | -51,659,206Source | -103,801,617Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -135,226,997Source | 15,359,713Source | -48,138,306Source | 51,561,597Source | 50,453,332Source | 19,733,609Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 156,574,345Source | — | 93,564,808Source | -40,341Source | -98,463Source | 45,020,474Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 1,384,484Source | 1,483,789Source | 11,334,370Source | 1,353,351Source | 9,776,400Source | 1,149,706Source | 3,496,540Source | 3,857,026Source | 4,091,568Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | 902,900Source | 3,448,400Source | 956,200Source | 3,572,800Source | 14,810,400Source | 30,184,400Source | 43,811,100Source | 44,194,800Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | — | 6,351,606Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 6,351,606Source |
| General and Administrative ExpenseUSD | — | — | 6,291,079Source | 11,859,702Source | 6,617,238Source | 7,401,929Source | 11,373,909Source | 6,267,412Source | 32,221,054Source | 37,715,524Source | 48,894,945Source | 47,926,077Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | -585,522Source |
| Investment Income, InterestUSD | — | — | 247,013Source | 856,478Source | 2,301,394Source | 321,458Source | 959,762Source | 440,287Source | 1,395,989Source | 3,530,021Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -10,091,496Source | -21,725,970Source | -12,914,185Source | -9,866,442Source | -19,051,956Source | -17,559,465Source | -57,385,163Source | -79,979,354Source | -98,791,746Source | -157,043,823Source |
| Nonoperating Income (Expense)USD | — | — | 235,850Source | 1,282,868Source | 2,096,842Source | 354,864Source | 409,798Source | 658,970Source | 1,715,037Source | 3,911,682Source | 4,910,547Source | 4,205,253Source |
| Operating ExpensesUSD | — | — | 10,327,346Source | 23,008,838Source | 15,011,027Source | 10,221,306Source | 19,461,754Source | 18,218,435Source | 59,100,200Source | 83,891,036Source | 103,702,293Source | 161,249,076Source |
| Operating Lease, ExpenseUSD | — | — | — | — | 47,500Source | 53,700Source | 45,700Source | 44,800Source | 190,700Source | 236,900Source | 14,500Source | — |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | — | 98,463Source | — |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 47,293,763Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 93,637,829Source | — | — | 42,728,599Source |
| Realized Investment Gains (Losses)USD | — | — | -81,438Source | 147,835Source | -37,294Source | 47,203Source | -9,867Source | 62,952Source | -79,207Source | 374,926Source | -4,064,391Source | -585,522Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | — | — | — | — | — | — | — | — | 62,386,500Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | 70,275Source | 278,555Source | -167,258Source | -13,797Source | -540,097Source | 155,731Source | 398,255Source | 6,735Source | 3,823,234Source | -4,220,255Source |
| Payments for Repurchase of Common Stock | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Proceeds from Stock Options Exercised | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -10,327,346Source | -23,008,838Source | -15,011,027Source | -10,221,306Source | -19,461,754Source | -18,218,435Source | -59,100,200Source | -83,891,036Source | -103,702,293Source | -161,249,076Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -10,091,496Source | -21,725,970Source | -12,914,185Source | -9,866,442Source | -19,051,956Source | -17,559,465Source | -57,385,163Source | -79,979,354Source | -98,791,746Source | -157,043,823Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.3Source | -0.72Source | -0.11Source | -0.3Source | -0.22Source | -0.58Source | -1.45Source | -2.65Source | -3.28Source | -5.3Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.3Source | -0.72Source | -0.11Source | -0.3Source | -0.22Source | -0.58Source | -1.45Source | -2.65Source | -3.28Source | -5.3Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 33,191,622Source | 30,174,202Source | 112,375,941Source | 33,191,622Source | 86,596,873Source | 30,408,890Source | 39,479,694Source | 30,163,751Source | 30,099,203Source | 29,628,664Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 33,191,622Source | 30,174,202Source | 112,375,941Source | 33,191,622Source | 86,596,873Source | 30,408,890Source | 39,479,694Source | 30,163,751Source | 30,099,203Source | 29,628,664Source |
| Additional Financial Items | ||||||||||||
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | — | 6,351,606Source |
| General and Administrative ExpenseUSD | — | — | 6,291,079Source | 11,859,702Source | 6,617,238Source | 7,401,929Source | 11,373,909Source | 6,267,412Source | 32,221,054Source | 37,715,524Source | 48,894,945Source | 47,926,077Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | -585,522Source |
| Interest and Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | — | 6,351,606Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | 5,151,704Source | 2,659,424Source |
| Investment Income, InterestUSD | — | — | 247,013Source | 856,478Source | 2,301,394Source | 321,458Source | 959,762Source | 440,287Source | 1,395,989Source | 3,530,021Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 235,850Source | 1,282,868Source | 2,096,842Source | 354,864Source | 409,798Source | 658,970Source | 1,715,037Source | 3,911,682Source | 4,910,547Source | 4,205,253Source |
| Operating ExpensesUSD | — | — | 10,327,346Source | 23,008,838Source | 15,011,027Source | 10,221,306Source | 19,461,754Source | 18,218,435Source | 59,100,200Source | 83,891,036Source | 103,702,293Source | 161,249,076Source |
| Operating Lease, ExpenseUSD | — | — | — | — | 47,500Source | 53,700Source | 45,700Source | 44,800Source | 190,700Source | 236,900Source | 14,500Source | — |
| Realized Investment Gains (Losses)USD | — | — | -81,438Source | 147,835Source | -37,294Source | 47,203Source | -9,867Source | 62,952Source | -79,207Source | 374,926Source | -4,064,391Source | -585,522Source |
| Research and Development ExpenseUSD | — | — | 4,036,267Source | 11,149,136Source | 8,393,789Source | 2,819,377Source | 8,087,845Source | 11,951,023Source | 26,879,146Source | 46,175,512Source | 54,807,348Source | 113,322,999Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | — | — | — | — | — | — | — | — | 62,386,500Source | — |
Offerings
Registration 333-295855
Registration 333-294885
Filing attachments
ea030099301ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 ea030099301ex99-1.htm PRESS RELEASE DATED AUGUST 6, 2026, REGARDING A CORPORATE UPDATE AND REPORTING ITS FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance. …
Read attachment ↗ea030099301ex99-2.htm · 8-K · 2026-08-06
EX-99.2 3 ea030099301ex99-2.htm CORPORATE PRESENTATION DATED AUGUST 6, 2026 Exhibit 99.2 Unlocking Life Changing Therapies Corporate Overview | August 2026 ©2026 Relmada - All rights reserved Disclosures 2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and…
Read attachment ↗ea029944901ex99-1.htm · 8-K · 2026-07-28
EX-99.1 2 ea029944901ex99-1.htm PRESS RELEASE ISSUED ON JULY 28, 2026 Exhibit 99.1 Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company’s long-term growth and value creation. CORAL GABLES, FL - July 28, 2026 (GlobeNewswire) - Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a cli…
Read attachment ↗ea029041401ex99-1.htm · 8-K · 2026-05-12
EX-99.1 2 ea029041401ex99-1.htm PRESS RELEASE DATED MAY 12, 2026, REGARDING CORPORATE UPDATE AND FULL YEAR 2025 FINANCIAL RESULTS Exhibit 99.1 Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR ra…
Read attachment ↗ea029041401ex99-2.htm · 8-K · 2026-05-12
EX-99.2 3 ea029041401ex99-2.htm CORPORATE PRESENTATION DATED MAY 12, 2026 Exhibit 99.2 Unlocking Life Changing Therapies May 2026 C O R P O R A T E O V E R V I E W ©2026 R elm ada - Al l ri ghts r eserved Disclosures 2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Ac…
Read attachment ↗ea028268801ex99-1.htm · 8-K · 2026-03-20
EX-99.1 2 ea028268801ex99-1.htm PRESS RELEASE DATED MARCH 19, 2026, REGARDING CORPORATE UPDATE AND FULL YEAR 2025 FINANCIAL RESULTS Exhibit 99.1 Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profile ───────────────────────…
Read attachment ↗